Abstract
In this prospective study, we examined the effect of atorvastatin treatment on baroreflex sensitivity (BRS) in subjects with type 2 diabetes. A total of 79 patients with type 2 diabetes with dyslipidaemia were recruited. A total of 46 subjects were enrolled to atorvastatin 10 mg daily and low-fat diet and 33 patients to low-fat diet only. BRS was assessed non-invasively using the sequence method at baseline, 3, 6 and 12 months. Treatment with atorvastatin increased BRS after 12 months (from 6.46 ± 2.79 ms/mmHg to 8.05 ± 4.28 ms/mmHg, p = 0.03), while no effect was seen with low-fat diet. Further sub-analysis according to obesity status showed that BRS increased significantly only in the non-obese group (p = 0.036). A low dose of atorvastatin increased BRS in non-obese subjects with type 2 diabetes and dyslipidaemia after 1-year treatment. This finding emphasizes the beneficial effect of atorvastatin on cardiovascular system, beyond the lipid-lowering effects.
Keywords:
Atorvastatin; autonomic function; baroreflex sensitivity; diabetes.
Publication types
-
Controlled Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Atorvastatin
-
Baroreflex / drug effects*
-
Body Mass Index
-
Cardiovascular Agents / adverse effects
-
Cardiovascular Agents / therapeutic use*
-
Cardiovascular Diseases / complications
-
Cardiovascular Diseases / epidemiology
-
Cardiovascular Diseases / etiology
-
Cardiovascular Diseases / prevention & control*
-
Combined Modality Therapy / adverse effects
-
Diabetes Mellitus, Type 2 / complications*
-
Diabetic Angiopathies / complications
-
Diabetic Angiopathies / epidemiology
-
Diabetic Angiopathies / etiology
-
Diabetic Angiopathies / prevention & control
-
Diabetic Cardiomyopathies / complications
-
Diabetic Cardiomyopathies / epidemiology
-
Diabetic Cardiomyopathies / etiology
-
Diabetic Cardiomyopathies / prevention & control
-
Diet, Fat-Restricted
-
Dyslipidemias / complications
-
Dyslipidemias / diet therapy
-
Dyslipidemias / drug therapy*
-
Dyslipidemias / physiopathology
-
Female
-
Greece / epidemiology
-
Heptanoic Acids / adverse effects
-
Heptanoic Acids / therapeutic use*
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Male
-
Middle Aged
-
Myalgia / chemically induced
-
Obesity / complications
-
Patient Dropouts
-
Prospective Studies
-
Pyrroles / adverse effects
-
Pyrroles / therapeutic use*
-
Risk Factors
Substances
-
Cardiovascular Agents
-
Heptanoic Acids
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Pyrroles
-
Atorvastatin